stoxline Quote Chart Rank Option Currency Glossary
Mirati Therapeutics, Inc. (MRTX)
56.69  0.04 (0.07%)    12-07 16:00
Open: 56.66
High: 56.79
Volume: 552,240
Pre. Close: 56.65
Low: 56.49
Market Cap: 3,977(M)
Technical analysis
2023-12-07 4:22:11 PM
Short term     
Mid term     
Targets 6-month :  66.78 1-year :  78
Resists First :  57.18 Second :  66.78
Pivot price 56.72
Supports First :  56.14 Second :  55.5
MAs MA(5) :  56.81 MA(20) :  56.59
MA(100) :  45.07 MA(250) :  43.59
MACD MACD :  0.6 Signal :  0.9
%K %D K(14,3) :  48.4 D(3) :  60.7
RSI RSI(14): 60
52-week High :  64.41 Low :  27.29
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MRTX ] has closed above bottom band by 45.4%. Bollinger Bands are 92.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 56.82 - 57.16 57.16 - 57.49
Low: 55.67 - 56.08 56.08 - 56.47
Close: 56.07 - 56.67 56.67 - 57.24
Company Description

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Headline News

Fri, 10 Nov 2023
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for ... - PR Newswire

Mon, 06 Nov 2023
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates - PR Newswire

Tue, 17 Oct 2023
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non ... - PR Newswire

Mon, 09 Oct 2023
Bristol Myers (BMY) to Acquire Mirati Therapeutics for $5.8 B - Yahoo Finance

Mon, 09 Oct 2023
Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal - Reuters

Sun, 08 Oct 2023
Bristol Myers to Buy Mirati Therapeutics for $4.8 Billion - Bloomberg

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 70 (M)
Held by Insiders 4.062e+007 (%)
Held by Institutions 6.8 (%)
Shares Short 4,660 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.6068e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 49.1 %
Return on Equity (ttm) -39.3 %
Qtrly Rev. Growth 3.819e+007 %
Gross Profit (p.s.) 280.55
Sales Per Share -97.16
EBITDA (p.s.) -7.2193e+008
Qtrly Earnings Growth -12.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -594 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.59
Price to Cash Flow 3.02
Stock Dividends
Dividend 0
Forward Dividend 6.09e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android